Commercialisation Plan Sample Clauses
A Commercialisation Plan clause outlines the strategy and steps for bringing a product, service, or intellectual property to market. It typically details the responsibilities of each party, timelines for key milestones, and the allocation of resources or funding required to achieve commercial objectives. By clearly defining the process and expectations for commercialisation, this clause helps ensure that all parties are aligned and reduces the risk of misunderstandings or delays in bringing the offering to market.
Commercialisation Plan. Pursuant to Article 5.5(a), the Joint Commercialisation Committee shall develop a Commercialisation Plan for each Antibody Product which shall:
(i) outline the overall strategy for the Commercialisation of each Antibody Product throughout the Territory;
(ii) adopt a budget for any Joint Activities;
(iii) consolidate the budgets of each Territorial Commercial Lead; and
(iv) address any other issue where the Parties wish to adopt a co-ordinated approach throughout the Territory. The Commercialisation Plan shall be first developed and approved by the Joint Commercialisation Committee no later than [*] before it is expected to file the first Drug Approval Application for an Antibody Product and shall be updated and approved as deemed necessary but at least annually, in time for the annual budget cycle of each of the Parties.
Commercialisation Plan. At least [***] during the Term, or more frequently as agreed by the Parties, ▇▇▇▇▇▇▇ shall provide Genmab with a summary of its and its Affiliates’ and sublicensees’ then current Commercialisation plan for the [***]. Subject to Clauses 4.2 and 4.3(B), all business decisions, including, without limitation, the design, sale, price and promotion of Licensed Products under this Agreement and the decisions whether to market any particular Licensed Product shall be within the sole discretion of ▇▇▇▇▇▇▇. [***], recognizing that the foregoing does not relieve ▇▇▇▇▇▇▇’▇ obligations under Clause 4.2 or Clause 4.3(B).
Commercialisation Plan. No later than six (6) months prior to the anticipated date of submission to any Regulatory Authority in any Major Market Country of the first application for a Marketing Authorisation for any Product (whether a Unitary Product or a Combination Product), sanofi pasteur shall prepare and provide to Emergent a Commercialisation Plan for such Product. That Commercialisation Plan shall include the matters referred to in the Outline Commercialisation Plan. sanofi pasteur shall consider in good faith any comments made by Emergent. Each Commercialisation Plan shall be updated by sanofi pasteur and submitted to the SC as provided for in this Clause 6.3 not less than annually. Within thirty (30) days of the submission of any Commercialisation Plan or any amendment or update to a Commercialisation Plan, the SC shall, if so requested by Emergent, meet to review and consider that plan or amendment.
Commercialisation Plan. Unless SRA agrees in writing that it is not required, the initial draft Commercialisation Plan provided by the Lead Research Provider is included in Schedule D setting out the Research Providers’ initial proposal for the Commercialisation of Project IP.
Commercialisation Plan. (a) The JCT shall develop, for approval by the Collaboration Committee, a Commercialisation Plan for Antibody Products, which Commercialisation Plan shall:
(i) outline the overall strategy for the Commercialisation of Antibody Products throughout the Territory, including the strategy for positioning of the Antibody Products;
(ii) identify manufacturing needs and requirements of Commercial Supplies of Antibody Products and identify an appropriate forecasting mechanism to provide the Manufacturer with sufficient lead-time to Manufacture and to supply the Parties’ requirements of Commercial Supplies of Antibody Products;
(iii) identify Joint Activities; and
(iv) address any other issue where the Parties wish to adopt a coordinated approach throughout the Territory.
(b) A proposed initial Commercialisation Plan for Antibody Products shall be developed and forwarded by the JCT to the Collaboration Committee, and the Collaboration Committee shall approve an initial Commercialisation Plan for Antibody Products no later than [***] [Confidential Treatment Required] before a Party is expected to file the first Drug Approval Application for an Antibody Product. Thereafter, the JCT shall review the Commercialisation Plan at least Quarterly, and shall make recommendations with respect to any updates or amendments thereto to the Collaboration Committee. Either Party may at any time propose an amendment to the Commercialisation Plan. Any such recommendations with respect to Agreed Indications shall include a good faith estimate of the budget for any such update or amendment, including any changes in the existing Commercialisation Budget. Each Party shall cooperate with the JCT in preparing such estimated budget. Subject to Article 6.7(b), all updates or amendments to the Commercialisation Plan must be approved by the Collaboration Committee or, if the Collaboration Committee cannot reach agreement on an update or amendment, the dispute resolution process set forth in Article 15.